Literature DB >> 28522572

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.

Carolina Schinke1, Antje Hoering2, Hongwei Wang2, Victoria Carlton3, Sharmilan Thanandrarajan4, Shayu Deshpande4, Purvi Patel4, Gabor Molnar4, Sandra Susanibar4, Meera Mohan4, Pankaj Mathur4, Muthukumar Radhakrishnan4, Shadiqul Hoque4, Jorge Jo Kamimoto4, Monica Grazziutti4, Frits van Rhee4, Maurizio Zangari4, Giovanni Insuasti-Beltran5, Daisy Alapat5, Ginell Post5, Shmuel Yaccoby4, Joshua Epstein4, Leo Rasche4, Sarah Johnson4, Martin Moorhead3, Tom Willis3, Bart Barlogie6, Brian Walker4, Niels Weinhold4, Faith E Davies4, Gareth J Morgan1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28522572      PMCID： PMC5541885          DOI： 10.3324/haematol.2017.165217

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Authors:  Andrzej J Jakubowiak; Dominik Dytfeld; Kent A Griffith; Daniel Lebovic; David H Vesole; Sundar Jagannath; Ammar Al-Zoubi; Tara Anderson; Brian Nordgren; Kristen Detweiler-Short; Keith Stockerl-Goldstein; Asra Ahmed; Terri Jobkar; Diane E Durecki; Kathryn McDonnell; Melissa Mietzel; Daniel Couriel; Mark Kaminski; Ravi Vij
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

2.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Curing myeloma at last: defining criteria and providing the evidence.

Authors:  Bart Barlogie; Alan Mitchell; Frits van Rhee; Joshua Epstein; Gareth J Morgan; John Crowley
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

4.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Malek Faham; Jianbiao Zheng; Martin Moorhead; Victoria E H Carlton; Patricia Stow; Elaine Coustan-Smith; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

5.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Authors:  Andy C Rawstron; J Anthony Child; Ruth M de Tute; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro-Coy; Mark T Drayson; Sylvia Feyler; Fiona M Ross; Gordon Cook; Graham H Jackson; Gareth J Morgan; Roger G Owen
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

Review 6.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

7.  Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.

Authors:  Juan José Lahuerta; Maria Victoria Mateos; Joaquin Martínez-López; Laura Rosiñol; Anna Sureda; Javier de la Rubia; José García-Laraña; Rafael Martínez-Martínez; Miguel T Hernández-García; Dolores Carrera; Joan Besalduch; Felipe de Arriba; José María Ribera; Lourdes Escoda; Belén Hernández-Ruiz; Javier García-Frade; Concepción Rivas-González; Adrían Alegre; Joan Bladé; Jesús F San Miguel
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

8.  Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Andy C Rawstron; Roger G Owen; J Anthony Child; Anjan Thakurta; Paul Sherrington; Mehmet Kemal Samur; Anna Georgieva; Kenneth C Anderson; Walter M Gregory
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777

9.  Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Authors:  Y Jethava; A Mitchell; M Zangari; S Waheed; C Schinke; S Thanendrarajan; J Sawyer; D Alapat; E Tian; C Stein; R Khan; C J Heuck; N Petty; D Avery; D Steward; R Smith; C Bailey; J Epstein; S Yaccoby; A Hoering; J Crowley; G Morgan; B Barlogie; F van Rhee
Journal:  Blood Cancer J       Date:  2016-09-16       Impact factor: 11.037

10.  Clinical value of molecular subtyping multiple myeloma using gene expression profiling.

Authors:  N Weinhold; C J Heuck; A Rosenthal; S Thanendrarajan; C K Stein; F Van Rhee; M Zangari; A Hoering; E Tian; F E Davies; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2015-11-03       Impact factor: 11.528
View more
  11 in total

1.  A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Kenneth C Anderson; Paola Neri; Bruno Paiva; Mehmet Samur; Meletios Dimopoulos; Margarita Kulakova; Annette Lam; Mahmoud Hashim; Jianming He; Bart Heeg; Jon Ukropec; Jessica Vermeulen; Sarah Cote; Nizar Bahlis
Journal:  Blood Adv       Date:  2020-12-08

Review 2.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 3.  Is molecular remission the goal of multiple myeloma therapy?

Authors:  Faith E Davies
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Future of CAR T cells in multiple myeloma.

Authors:  Kitsada Wudhikarn; Sham Mailankody; Eric L Smith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

5.  Minimal residual disease in multiple myeloma: why, when, where.

Authors:  Andrew J Yee; Noopur Raje
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

6.  Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.

Authors:  Katja Weisel; Maria-Victoria Mateos; Francesca Gay; Michel Delforge; Gordon Cook; Zsolt Szabo; Renaud Desgraz; Lucy DeCosta; Philippe Moreau
Journal:  Leukemia       Date:  2020-10-16       Impact factor: 11.528

7.  Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Authors:  L Rasche; D Alapat; M Kumar; G Gershner; J McDonald; C P Wardell; R Samant; R Van Hemert; J Epstein; A F Williams; S Thanendrarajan; C Schinke; M Bauer; C Ashby; R G Tytarenko; F van Rhee; B A Walker; M Zangari; B Barlogie; F E Davies; G J Morgan; N Weinhold
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

8.  Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.

Authors:  David Baker; Milan Bimali; Luis Carrillo; Archana Sachedina; Daisy Alapat; Md Shadiqul Hoque; Mathew Kottarathara; Richa Parikh; Amani Erra; Angel A Mitma; Pankaj Mathur; Yetunde Ogunsesan; Lakshmi Yarlagadda; Sravani Gundarlapalli; Sharmilan Thanendrarajan; Maurizio Zangari; Frits Van Rhee; Guido Tricot; Carolina Schinke
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941

Review 9.  Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications.

Authors:  Charalampos Charalampous; Taxiarchis Kourelis
Journal:  Front Oncol       Date:  2022-01-26       Impact factor: 6.244

10.  Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.

Authors:  Meera Mohan; Samantha Kendrick; Aniko Szabo; Naveen Yarlagadda; Dinesh Atwal; Yadav Pandey; Arya Roy; Richa Parikh; James Lopez; Sharmilan Thanendrarajan; Carolina Schinke; Daisy Alapat; Jeffrey Sawyer; Erming Tian; Guido Tricot; Frits van Rhee; Maurizio Zangari
Journal:  Blood Adv       Date:  2022-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.